Hwangeun Choi

USPTO Granted Patents = 5 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 5.0

ph-index = 1

Company Filing History:

5 out of 1,210

Dana-farber-cancer Institute Inc.

where one patent can have more than one assignee

Years Active: 2021-2025

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12479847 - Pyrrolopyrimidine inhibitors of wild-type and mutant forms of LRRK2 (2025-11-25),

2. 12275731 - Azaindole inhibitors of wild-type and mutant forms of LRRK2 (2025-04-14),

3. 12157741 - Macrocyclic inhibitors of DYRK1A (2024-12-03),

4. 11858897 - Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPK (2024-01-02),

5. 11066363 - Substituted 6,11-dihydro-5H-benzo[B]carbazoles as inhibitors of ALK and SRPK (2021-07-20),

Title: Inventor Hwangeun Choi

Introduction: Hwangeun Choi is a renowned inventor based in Seoul, South Korea, known for his groundbreaking contributions to various technological fields.

Latest Patents: Hwangeun Choi holds several patents in the areas of electronics, telecommunications, and renewable energy, showcasing his innovative mindset and expertise in these domains.

Career Highlights: With a career spanning over two decades, Hwangeun Choi has worked with leading research institutions and companies to develop cutting-edge technologies that have had a significant impact on the industry.

Collaborations: Throughout his career, Hwangeun Choi has collaborated with top engineers, scientists, and inventors globally, fostering a culture of innovation and knowledge sharing in the field.

Conclusion: Hwangeun Choi's dedication to pushing the boundaries of technology and his passion for innovation continue to inspire the next generation of inventors and researchers worldwide.

This text is generated by artificial intelligence and may not be accurate.